Immunovant
IMVT
IMVT
147 hedge funds and large institutions have $1.05B invested in Immunovant in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 57 increasing their positions, 45 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
4% more funds holding
Funds holding: 142 → 147 (+5)
2.2% less ownership
Funds ownership: 44.73% → 42.53% (-2.2%)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Holders
147
Holding in Top 10
3
Calls
$14.6M
Puts
$10.5M
Top Buyers
| 1 | +$23.4M | |
| 2 | +$21M | |
| 3 | +$19.8M | |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$11.5M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$11M |
Top Sellers
| 1 | -$39.7M | |
| 2 | -$38.2M | |
| 3 | -$21.6M | |
| 4 |
CAC
Cowen and Company
New York
|
-$19.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$16.3M |